Turning a ‘Don’t-Eat-Me’ Signal into a Universal Tumor Weakness
Cancer cells evade immune destruction by hijacking the CD47–SIRPα pathway. We’ve flipped that biology on its head – developing an engineered SIRPα (eSIRPα) – conjugate that homes to tumors to deliver a potent therapeutic payload with unprecedented selectivity.
By directing payload delivery through the CD47 receptor, which is widely upregulated in cancer cells, K2B’s breakthrough approach enables:
- Selective intracellular delivery of payloads to cancer cells
- High tumor penetration and rapid systemic clearance
- Tumor agnostic targeting and efficacy
